|A010-214||SARS-CoV-2 Spike RBD||10 μg||60 μg|
|A011-214||Biotinylated Human ACE2||10 μg||10 μg|
|A003-214||Streptavidin-HRP||10 μg||10 μg|
|AC2-NA005||SARS-CoV-2 Inhibitor (Human ACE2)||20 μg||50 μg|
Upon receipt, please store all items at -20℃ to -70℃. After reconstitution, the stock solution should be kept at -70℃.
It is recommended not to freeze thaw more than 3 times.
Your experiment will include 4 simple steps:
a) Coat the plate with SARS-CoV-2 S protein RBD.
b) Add 50ul biotinylated human ACE2 to coated plate.
c) Add the reference or your molecule of interest.
d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.
Finally, the ability of your compound to inhibit S protein RBD: ACE2 binding will be determined by comparing OD readings among different experimental groups.
Binding of Biotinylated Human ACE2 To Immobilized SARS-CoV-2 S protein RBD In A Functional ELISA Assay.
Immobilized 2019-CoV-2 S protein RBD at 0.5 μg/mL (100 μL/well) can bind human ACE2-Biotin with a linear range of 0.001- 0.06 μg/mL when detected by Streptavidin-HRP. Background was subtracted from data points before curve fitting.
Inhibition of Human ACE2 [Biotinylated] :SARS-CoV-2 S protein RBD Binding by SARS-CoV-2 inhibitor.
Serial dilutions of SARS-CoV-2 inhibitor (Cat. No. AC2-NA005) (1:2 serial dilutions, from 20 μg/mL to 0.039 μg/mL (180 nM to 0.35 nM)) was added into Biotinylated ACE2: SARS-CoV-2 S protein RBD binding reactions. The assay was performed according to the above described protocol. Background was subtracted from data points prior to log transformation and curve fitting.
Price(USD) : $600.00
Price(USD) : $2150.00
Price(USD) : $100.00
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.